Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales.
By Cynthia Koons
Humira, a treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis made by AbbVie Inc. is the planet’s best-selling drug. It’s also been around almost 15 years. Those two facts alone would normally have rival drugmakers eagerly circling, ready to roll out generic versions that could win a piece of the aging medicine’s $16 billion in annual sales. Yet last year, when the patent on Humira’s main ingredient expired, not a single competitor launched a copycat version. Figuring out how to manufacture it wasn’t the obstacle. The real challenge was the seemingly impregnable fortress of patents AbbVie has methodically constructed around its prized moneymaker. Continue reading
In an open letter and open submission, thirty-three civil society organisations have called on the European Commission to abolish the supplementary protection certificates (SPC) mechanism and to stop encouraging the inclusion of SPCs – or similar mechanisms, such as patent term extensions – in free trade agreements with other countries.
Supplementary protection certificates (SPCs) expand and extend existing monopoly rights of pharmaceutical corporations. As such, SPCs lead to higher medicines prices by preventing generic competition for a longer period of time and prolonging the monopolies of originator pharmaceutical companies.
By Carmen Paun
9/11/17, 1:43 PM CET
A group of 33 civil society organizations led by Doctors Without Borders today asked the European Commission to abolish supplementary protection certificates (SPCs), which they claim lead to unaffordable medicines prices that stay in place for longer periods of time.
The group’s call comes as the Commission is reviewing a 2009 regulation governing the certificates, which are used to cover the time between obtaining patent protection for a drug and its market authorization. A meeting on the subject is taking place today in Munich, convened by the Max Planck Institute, which is conducting a study that will be used as part of the Commission’s review. Continue reading
Source: PTI Published: Zee News
A bench of Acting Chief Justice Gita Mittal and Justice C Hari Shankar also issued notice to the Delhi Government on the petition which sought direction to identify and publicise the names of hospitals, laboratories and medical stores which will provide testing and treatment of Hepatitis C virus (HCV) free of cost in the national capital.
New Delhi: A plea seeking directions to authorities on testing and treatment of the deadly Hepatitis C, including free diagnostics and medication to patients, today prompted the Delhi High Court to ask the Delhi government to file a status report on the matter. Continue reading
Today, UACT submitted letters to the CEOs of three major pharmaceutical companies currently developing chimeric antigen receptor T-cell (CAR T) technologies. UACT asked the leaders of Novartis, Gilead Sciences, and Juno Therapeutics to address questions regarding research and development (R&D) costs, federal-funding received, potential public health impact, and ensuring equitable and affordable access to CAR T treatments in the US and around the world. Continue reading
Govt will lose gold mine dispute due to Article 44 use: academics
By PRATCH RUJIVANAROM The Nation (Thailand) | 1 Sep 2017
BANGKOK: — Experts and academics have warned that Thailand will lose an arbitral tribunal process regarding allegations that it violated the Thailand-Australia Free Trade Agreement (TAFTA), because of the exercise of special powers under Article 44 of the interim constitution that are not recognised by the international community.
Kannikar Kijtiwatchakul, coordinator of FTA Watch, warned that Thailand had a very small chance of winning the dispute regarding the closure of a gold mine, exposing the country to huge losses due to claims for compensation. Continue reading
Create, Copy, Disrupt: India’s Intellectual Property Dilemmas is well-researched and easy to read, especially for a non-legal audience.
By Jayashree Watal, The Wire
The book Create, Copy, Disrupt: India’s Intellectual Property Dilemmas (OUP, 2017) is a serious effort by two legal scholars, Prashant Reddy T. and Sumathi Chandrashekaran, to explain some of India’s most controversial intellectual property (IP) issues to a non-legal audience. It is a painstakingly well-researched book that was clearly also aimed at providing new nuggets of information and analysis to IP scholars, thus making it a book that takes on the difficult task of simultaneously seeking approval from two very different audiences. But this is a timely publication as it is high time someone gave us the full background and context of the more interesting IP policy issues that India has had to grapple with over the last seven decades since its independence. Therefore, this book ought to have a wider audience than just IP scholars. Continue reading